Durable response to crizotinib in a MET-amplified, KRAS-mutated carcinoma of unknown primary

Case Reports in Oncology

Volumn 7, Issue 2, 2014, Pages 503-508

  Palma, Norma A ^a   Ali, Siraj M ^a   O'Connor, Jamie ^e   Dutta, Deepa ^b   Wang, Kai ^a   Soman, Salil ^c   Palmer, Gary A ^a   Morosini, Deborah ^a   Ross, Jeffrey S ^a   Lipson, Doron ^a   Stephens, Phil J ^a   Patel, Mayur ^d   Miller, Vincent A ^a   Koutrelakos, Nicholas ^e  

^a FOUNDATION MEDICINE   (United States)

^b SINAI HOSPITAL OF BALTIMORE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d American Radiology Services   (United States)

^e Maryland Oncology Hematology   (United States)

Author keywords

Carcinoma of unknown primary; Crizotinib; KRAS mutation; MET amplification; Next generation sequencing

Indexed keywords

CARBOPLATIN; CRIZOTINIB; CYCLIN D1; CYTOKERATIN 7; DOCETAXEL; EPITHELIAL MEMBRANE ANTIGEN; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; K RAS PROTEIN; MYC PROTEIN; PROTEIN P53; SCATTER FACTOR RECEPTOR; THYROID TRANSCRIPTION FACTOR 1;

ABDOMINAL MASS; ADULT; ARTICLE; BRAIN DAMAGE; BRAIN EDEMA; BRAIN METASTASIS; BRAIN SURGERY; CANCER OF UNKNOWN PRIMARY SITE; CANCER SURGERY; CASE REPORT; CLINICAL EFFECTIVENESS; CODON; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COPY NUMBER VARIATION; DISEASE COURSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FRONTAL LOBE; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE MUTATION; GENE REARRANGEMENT; GENETIC CODE; GENETIC IDENTIFICATION; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INDEL MUTATION; INTRON; MEDICAL HISTORY; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEEDLE BIOPSY; NEUROIMAGING; NEXT GENERATION SEQUENCING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEIZURE; SMOKING; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84924035738     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000365326     Document Type: Article

References (13)

1. Massard C, Loriot Y, Fizazi K: Carcinomas of an unknown primary origin-diagnosis and treatment. Nat Rev Clin Oncol 2011;8:701-710
2. Tan DSW, Montoya J, Ng QS, et al: Molecular profiling for druggable genetic abnormalities in carcinoma of unknown primary. J Clin Oncol 2013;31:e237-e239
3. Ross JS: Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy. Drug News Perspect 2009;22:93-106
4. Frampton GM, Fichtenholtz A, Otto GA, et al: Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31:1023-1031
5. Ou SHI, Kwak EL, Siwak-Tapp C, et al: Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011;6:942-946
6. Ross JS, Ali SM, Wang K, et al: Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies. Gynecol Oncol 2011;130:554-559
7. Ross JS, Wang K, Al-Rohil RN, et al: Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. Mod Pathol 2014;27:271-280
8. Schwab R, Petak I, Kollar M, et al: Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement. Lung Cancer 2014;83:109-111
9. Lennerz JK, Kwak EL, Ackerman A, et al: MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011;29:4803-4810
10. Chi AS, Batchelor TT, Kwak EL, et al: Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor. J Clin Oncol 2012;30:e30-e33
11. Neuzillet C, Tijeras-Raballand A, de Mestier L, et al: MEK in cancer and cancer therapy. Pharmacol Ther 2014;141:160-171
12. Gainor JF, Varghese AM, Ou S-HI, et al: ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res 2013;19:4273-4281
13. Sequist LV, von Pawel J, Garmey EG, et al: Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011;29:3307-3315.